Objectives - Rare tumors are diagnostic challenges for pathologists. Consultation or referral to Centers with expertise is crucial for the right diagnosis. This is particularly true for Thymic Epithelial Tumors (TETs), whose treatment strategies vary according to histological subgroup. We aimed at evaluating the accuracy of TET pathologic characterization in an Italian reference Center. Materials and methods - All the cases with diagnosis or suspicion of TETs, which underwent a pathological second opinion at Istituto Nazionale dei Tumori (INT), Milan, between 2015 and 2019 were retrospectively reviewed. All cases had been pathologically characterized through immunohistochemistry (IHC). Descriptive statistics were used for qualitative variables. Concordance was estimated through Cohen's kappa (k). Results - Out of 278 cases of TETs diagnosed in INT, 72 were referred to INT for a pathologic revision. The INT revision changed the diagnosis in 41 cases (56.9%), with a potential therapeutic shift in 32 (44.4%). In particular, 20 cases of thymoma were reviewed as a different subtype of thymoma (19/20) or lymphoma (1/20); nine cases of thymic carcinoma were reviewed as thymoma. On the other hand, three cases of lung carcinoma were reviewed as thymic carcinoma (2/3) or thymoma (1); eight cases of carcinoma Not Otherwise Specified were reviewed as thymic carcinoma; one case of lymphoma was reviewed as thymoma. Concordance between pathologists was moderate for thymoma (74.7%, k 0.447), inferior for thymic carcinoma (60.5%, k 0.139). Conclusion - A significant proportion of cases referred to INT for a presumptive TET received a different characterization. A potential shift in therapeutic indication was not rare. This underlines the importance for TETs to get a second pathological diagnosis by an expert pathologist and supports the need for networks on rare cancers. © 2020 Elsevier B.V.

Accuracy of pathologic diagnosis for thymic epithelial tumors: a brief report from an Italian reference Center / G. Galli, A. Trama, L. Abate-Daga, M. Brambilla, M. Chiara Garassino, A. Fabbri. - In: LUNG CANCER. - ISSN 0169-5002. - 146(2020 Aug), pp. 66-69. [10.1016/j.lungcan.2020.05.007]

Accuracy of pathologic diagnosis for thymic epithelial tumors: a brief report from an Italian reference Center

G. Galli
Primo
;
M. Brambilla;
2020

Abstract

Objectives - Rare tumors are diagnostic challenges for pathologists. Consultation or referral to Centers with expertise is crucial for the right diagnosis. This is particularly true for Thymic Epithelial Tumors (TETs), whose treatment strategies vary according to histological subgroup. We aimed at evaluating the accuracy of TET pathologic characterization in an Italian reference Center. Materials and methods - All the cases with diagnosis or suspicion of TETs, which underwent a pathological second opinion at Istituto Nazionale dei Tumori (INT), Milan, between 2015 and 2019 were retrospectively reviewed. All cases had been pathologically characterized through immunohistochemistry (IHC). Descriptive statistics were used for qualitative variables. Concordance was estimated through Cohen's kappa (k). Results - Out of 278 cases of TETs diagnosed in INT, 72 were referred to INT for a pathologic revision. The INT revision changed the diagnosis in 41 cases (56.9%), with a potential therapeutic shift in 32 (44.4%). In particular, 20 cases of thymoma were reviewed as a different subtype of thymoma (19/20) or lymphoma (1/20); nine cases of thymic carcinoma were reviewed as thymoma. On the other hand, three cases of lung carcinoma were reviewed as thymic carcinoma (2/3) or thymoma (1); eight cases of carcinoma Not Otherwise Specified were reviewed as thymic carcinoma; one case of lymphoma was reviewed as thymoma. Concordance between pathologists was moderate for thymoma (74.7%, k 0.447), inferior for thymic carcinoma (60.5%, k 0.139). Conclusion - A significant proportion of cases referred to INT for a presumptive TET received a different characterization. A potential shift in therapeutic indication was not rare. This underlines the importance for TETs to get a second pathological diagnosis by an expert pathologist and supports the need for networks on rare cancers. © 2020 Elsevier B.V.
diagnosis; histology; networking; rare diseases; thymic epithelial tumors;
Settore MED/06 - Oncologia Medica
ago-2020
27-mag-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
Figure 1.tif

accesso aperto

Tipologia: Altro
Dimensione 10.22 kB
Formato TIFF
10.22 kB TIFF Visualizza/Apri
Suplementary figure 1.tif

accesso aperto

Tipologia: Altro
Dimensione 889.06 kB
Formato TIFF
889.06 kB TIFF Visualizza/Apri
Supplementary figure 2.tif

accesso aperto

Tipologia: Altro
Dimensione 838.23 kB
Formato TIFF
838.23 kB TIFF Visualizza/Apri
Supplementary figure 3.tif

accesso aperto

Tipologia: Altro
Dimensione 973.37 kB
Formato TIFF
973.37 kB TIFF Visualizza/Apri
Manuscript R1 clean-1.pdf

Open Access dal 28/05/2021

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 99.39 kB
Formato Adobe PDF
99.39 kB Adobe PDF Visualizza/Apri
Tables.pdf

accesso aperto

Tipologia: Altro
Dimensione 45.79 kB
Formato Adobe PDF
45.79 kB Adobe PDF Visualizza/Apri
Highlights.pdf

accesso aperto

Tipologia: Altro
Dimensione 23.29 kB
Formato Adobe PDF
23.29 kB Adobe PDF Visualizza/Apri
1-s2.0-S0169500220304281-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 219.59 kB
Formato Adobe PDF
219.59 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/742365
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact